Study of blood markers and chemotherapy response in breast cancer
Part of Cancer, Skin clinical trials.
This trial is studying tiny molecules in your blood (called microRNAs) to see if they can predict how well breast cancer responds to chemotherapy given before surgery. If you are starting neoadjuvant chemotherapy, this study may help personalize your treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have been diagnosed with breast cancer (confirmed by a biopsy).
- You are planning to get chemotherapy before surgery (neoadjuvant chemotherapy).
- You are biologically female.
- You are 18 years old or older.
- You are able to give informed consent.
- Your organs are working well enough for standard chemotherapy (your doctor will check this).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial looks at tiny particles called exosomes from your blood and leftover tumor tissue to see if they can predict how well chemotherapy works before surgery. The goal is to find markers that help doctors choose the best treatment for you.
This study checks whether a blood test that looks for “tumor DNA” (circulating tumor DNA) can help evaluate how well neoadjuvant chemotherapy worked for breast cancer. It may help doctors better understand treatment response after surgery.
This study tests whether using a personalized approach to treatment after chemotherapy can improve outcomes for people with HER2-positive or triple-negative breast cancer. It aims to tailor further therapy based on how well the tumor responds initially.
This study looks at how well a computer model can predict if breast cancer will completely respond to chemotherapy before surgery. It is for people with early-stage breast cancer who are about to start neoadjuvant chemotherapy.
This trial studies small particles in the blood (called extracellular vesicles) in people receiving chemotherapy before surgery for breast cancer. It may help doctors learn more about what those particles can tell them during neoadjuvant treatment.
This trial tests whether a blood test (ctDNA) can help doctors monitor how well chemotherapy before surgery is working in women with HER2-positive breast cancer. It aims to see if changes in the blood can predict treatment success.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.